Contribute Try STAT+ Today

A version of this article first appeared in D.C. Diagnosis, STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.

WASHINGTON — Two top Food and Drug Administration officials, suddenly at the center of the White House’s effort to speed approval for Covid-19 vaccines, will recuse themselves from the agency’s considerations about whether to approve those products, according to an email obtained by STAT.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • So Japan approving REMDESIVIR and the EMA’s imminent aprroval of remdesivir would also be regarded as
    questionable requiring careful review of everyone involved for their potential conflict of interest? Should someone from activist group be included for the covid-19 drug or biologics review processbin order to placate them? Ridiculous!

Comments are closed.